Evidence map›Paper›PMID 30857774›Full record

Observational studyThe Journal of pediatrics2019

Respiratory Medications in Infants <29 Weeks during the First Year Postdischarge: The Prematurity and Respiratory Outcomes Program (PROP) Consortium.

Rita M Ryan, Roberta L Keller, Brenda B Poindexter, Carl T D'Angio, Pamela A Shaw, Scarlett L Bellamy, Paul E Moore, Christopher McPherson, James M Greenberg, PROP Investigators

Open access · greenAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Journal of pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. An Update on the Prevention and Management of Bronchopulmonary Dysplasia.Pediatric health, medicine and therapeutics · 2021
    Review
  9. Inhaled bronchodilator exposure in the management of bronchopulmonary dysplasia in hospitalized infants.Journal of perinatology : official journal of the California Perinatal Association · 2021
    Article
  10. Article
  11. Preemie Brains Don't Like Mechanical Ventilation!The Journal of pediatrics · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Rita M RyanDepartment of Pediatrics, Medical University of South Carolina, Charleston, SC. Electronic address: ryanr@musc.edu.
Roberta L KellerDepartment of Pediatrics, University of California-San Francisco, San Francisco, CA.
Brenda B PoindexterDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Carl T D'AngioDepartment of Pediatrics, University of Rochester, Rochester, NY.
Pamela A ShawDepartment of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA.
Scarlett L BellamyDepartment of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA.
Paul E MooreDepartment of Pediatrics, Vanderbilt University, Nashville, TN.
Christopher McPhersonDepartment of Pediatrics, Washington University, St Louis, MO.
James M GreenbergDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
PROP Investigators
Cincinnati Children's Hospital Medical Center · USUniversity of Pennsylvania · USUniversity of California, San Francisco · USWashington University in St. Louis · USMedical University of South Carolina · USUniversity of Rochester · USVanderbilt University · US

Funding

Data Coordinating Center for the Prematurity and Respiratory Outcomes ProgramU01HL101794 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI SCHMIDT, BARBARA · 2010 to 2014
$10.3M
Gastrin-Releasing Peptide and Bronchopulmonary DysplasiaR01HL105702 · NHLBI · DUKE UNIVERSITY · PI COTTEN, CHARLES MICHAEL, DAVIS, STEPHANIE DUGGINS · 2011 to 2015
$2.8M
Biomarkers of Immunologic Function and Preterm Respiratory OutcomesU01HL101800 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI CHOUGNET, CLAIRE A., JOBE, ALAN H · 2010 to 2014
$2.5M
Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic PreemiesU01HL101813 · NHLBI · UNIVERSITY OF ROCHESTER · PI MARIANI, THOMAS J, PRYHUBER, GLORIA S · 2010 to 2014
$2.4M
Improving Prematurity-related Respiratory Outcomes at Vanderbilt (IMPROV)U01HL101456 · NHLBI · VANDERBILT UNIVERSITY · PI ASCHNER, JUDY LYNN · 2010 to 2014
$2.4M
UCSF Clinical Research Center for Prematurity and Respiratory Outcomes ProgramU01HL101798 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BALLARD, PHILIP L., KELLER, ROBERTA L · 2010 to 2014
$2.1M
Influence of the Enteric Microbiome on the Genesis of Bronchopulmonary DysplasiaU01HL101465 · NHLBI · WASHINGTON UNIVERSITY · PI FERKOL, THOMAS W, WARNER, BARBARA B · 2010 to 2014
$2.1M
NHLBI NIH HHS R01 HL105702NHLBI NIH HHS U01 HL101456NHLBI NIH HHS U01 HL101465NHLBI NIH HHS U01 HL101794NHLBI NIH HHS U01 HL101798NHLBI NIH HHS U01 HL101800NHLBI NIH HHS U01 HL101813
6 · The paper itself

Abstract

objectiveTo determine patterns of respiratory medications used in neonatal intensive care unit graduates. STUDY

designThe Prematurity Respiratory Outcomes Program enrolled 835 babies <29 weeks of gestation in the first week. Of 751 survivors, 738 (98%) completed at least 1, and 85% completed all 4, postdischarge medication usage in-person/telephone parental questionnaires requested at 3, 6, 9, and 12 months of corrected age. Respiratory drug usage over the first year of life after in neonatal intensive care unit discharge was analyzed.

resultsDuring any given quarter, 66%-75% of the babies received no respiratory medication and 45% of the infants received no respiratory drug over the first year. The most common postdischarge medication was the inhaled bronchodilator albuterol; its use increased significantly from 13% to 31%. Diuretic usage decreased significantly from 11% to 2% over the first year. Systemic steroids (prednisone, most commonly) were used in approximately 5% of subjects in any one quarter. Inhaled steroids significantly increased over the first year from 9% to 14% at 12 months. Drug exposure changed significantly based on gestational age with 72% of babies born at 23-24 weeks receiving at least 1 respiratory medication but only 40% of babies born at 28 weeks. Overall, at some time in the first year, 55% of infants received at least 1 drug including an inhaled bronchodilator (45%), an inhaled steroid (22%), a systemic steroid (15%), or diuretic (12%).

conclusionMany babies born at <29 weeks have no respiratory medication exposure postdischarge during the first year of life. Inhaled medications, including bronchodilators and steroids, increase over the first year.

Indexed as

Administration, InhalationAnti-Inflammatory AgentsBronchodilator AgentsBronchopulmonary DysplasiaDiureticsFemaleGestational AgeHumansInfantInfant, NewbornInfant, PrematureInfant, Premature, DiseasesIntensive Care Units, NeonatalMaleOxygenPatient DischargeAnti-Inflammatory AgentsBronchodilator AgentsDiureticsOxygenPrednisoneSteroidsbronchopulmonary dysplasiadrugprematurity

Identifiers

PMID30857774
PMCPMC6486865
OpenAlexW2922435315

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.